ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
 PMID: 19152409       2009       Journal of medical virology
Abstract: In addition to the YMDD mutations, the rtL180M, rtL80I, and rtV173L mutations were also present in 78%, 43%, and 11% of patients, respectively.
Abstract: The rtM204V mutation always accompanied rtL180M, and rt
Abstract: The presence of the rtL180M, rtL80I, and rtV173L did not significantly affect viral load reduction during adefovir administration.


  Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
 PMID: 19178592       2009       HIV medicine
Abstract: The previously identified putative TDF-resistance mutations, rtA194T+rtL180M+rtM204V, were not detected in any individual.


  Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.
 PMID: 19274751       2009       Hepatology (Baltimore, Md.)
Abstract: The polymerase gene mutant contained a combination of three mutations (rtV173L, rtL180M, rtM204V), two of which resulted in changes to the overlapping viral envelope of the hepatitis B surface antigen (sE164D, sI195M).


  Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.
 PMID: 19280622       2009       Hepatology (Baltimore, Md.)
Abstract: Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V +/- L180M.


  Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
 PMID: 19301976       2009       The Journal of infectious diseases
Abstract: UDPS detected drug-resistance mutations that were not detected by PCR in 10 samples from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and S202G (in 1 sample), the adefovir-resistance mutation N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180M, A181T, and M204V (in 1 sample).
Discussion: However, in 5 other samples, UDPS detected cross-resistance mutations, including the ADV-resistance mutation rtN236T, the ETV-resistance mutations rt


  Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
 PMID: 19302908       2009       Clinical therapeutics
Abstract: A total of 9.1% (4/44) of the clones harbored the rtL180M + rtT184L + rtM204I mutations.
Abstract: At week 22 during ADV treatment, LAM-resistance mutations (rtL180M, rtT184L, rtM204I, rtV191I, and rtL229V) were not detected.
Abstract: The rtM204I mutation was associated with compensatory mutations (rt


  Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
 PMID: 19323782       2009       Liver international
Abstract: The rtL80V/I and rtL180M variants were identified in 66 (68%) and 67 (69%) patients respectively.
Abstract: The rtM204I and rtM204V variants were strongly associated with rtL80V/I and rtL180M respectively (P<0.01).
Abstract: There was no difference in antiviral response at 12 months after ADV therapy between patients in relation to the type of YMDD mutation or the presence of rtL180M.


  Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
 PMID: 19398648       2009       Antimicrobial agents and chemotherapy
Abstract: HDP-(S)-HPMPA retained full activity against HBV mutants resistant to lamivudine (L180M, M204V), but cross-resistance to a mutant resistant to adefovir (N236T) was detected.


  Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.
 PMID: 19475333       2009       Journal of gastroenterology
Abstract: An entecavir-resistant virus having rtM204V, rtL180M and rtS202G substitutions was detected in this patient.


  Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
 PMID: 19475624       2009       Journal of medical virology
Abstract: In this latter group, the prevalence of the rtV173L + rtL180M + rtM204V triple mutation was 31% versus a prevalence of 3.4% observed among patients infected with HBV only.



Browser Board

 Co-occurred Entities




   Filtrator